# Modulating the Endocannabinoid System in Alcohol Use Disorder: A Translational Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/modulating-endocannabinoid-system-alcohol-use-disorder/ > **Published:** 2026-03-20T17:44:26-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T15:55:01-04:00 > **Clinical Summary:** Explore modulating endocannabinoid system alcohol use disorder with latest research on cannabinoid effects and therapeutic potential for AUD treatment. --- CED Clinical Relevance  #89High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic Alcohol Use DisorderCbdAddictionSystematic Review[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/) Journal Molecular psychiatry Study Type Systematic Review Population Human participants Why This Matters This comprehensive systematic review provides the most rigorous evidence synthesis to date on targeting the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) for [alcohol use disorder treatment](https://cedclinic.com/herbicide-cancer-risks-cannabis-cultivation-safety/). With limited FDA-approved options for AUD and promising preclinical data on [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/), this analysis helps clarify which endocannabinoid interventions show therapeutic potential. Clinical Summary This systematic review and meta-analysis examined 63 preclinical and human studies evaluating endocannabinoid system modulators for alcohol use disorder. Preclinical meta-analyses demonstrated that CB-1 receptor inverse agonists significantly reduced alcohol intake (SMD = -1.21), as did CBD (SMD = -0.70), while CB-1 agonists increased consumption (SMD = +0.66). Dose-response analyses revealed non-linear effects for both CB-1 inverse agonists and CBD. Human studies showed methodological heterogeneity that precluded meta-analysis, highlighting the early stage of [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) in this area. Dr. Caplan’s Take “While these preclinical findings are compelling, I remain cautious about extrapolating to clinical practice given the limited and heterogeneous human data. The mechanisms are biologically plausible, but we need well-designed human trials before considering endocannabinoid modulators as evidence-based AUD treatments.” Clinical Perspective 🧠 Clinicians should view this as promising foundational research rather than practice-changing evidence. Patients with AUD asking about cannabis interventions should understand that while preclinical data suggests potential benefit from CBD and harm from THC-dominant products, robust human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are still needed to establish safety and efficacy. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Modulating%20the%20endocannabinoid%20system%20in%20alcohol%20use%20disorder%3A%20A%20translational%20s...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41760917/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41760917/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Modulating%20the%20endocannabinoid%20system%20in%20alcohol%20use%20disorder%3A%20A%20translational%20s...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41760917/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41760917/](https://pubmed.ncbi.nlm.nih.gov/41760917/) Table of Contents - [FAQ](#FAQ)[What did this review study about cannabinoids and alcohol use disorder?](#What_did_this_review_study_about_cannabinoids_and_alcohol_use_disorder) - [Did CBD reduce alcohol intake in the studies reviewed?](#Did_CBD_reduce_alcohol_intake_in_the_studies_reviewed) - [Did CB-1 agonists affect alcohol consumption in the review?](#Did_CB-1_agonists_affect_alcohol_consumption_in_the_review) - [Does a higher dose of CBD lead to a bigger reduction in drinking?](#Does_a_higher_dose_of_CBD_lead_to_a_bigger_reduction_in_drinking) - [What do human studies show about endocannabinoid treatments for alcohol use disorder?](#What_do_human_studies_show_about_endocannabinoid_treatments_for_alcohol_use_disorder) - [Related](#Related) ## FAQ ### What did this review study about cannabinoids and alcohol use disorder? It is a systematic review and meta-analysis, published in Molecular Psychiatry, that examined 63 preclinical and human studies. These studies evaluated compounds that modulate the endocannabinoid system as potential treatments for alcohol use disorder, including CB-1 receptor inverse agonists, CB-1 agonists, and CBD. ### Did CBD reduce alcohol intake in the studies reviewed? In the preclinical meta-analyses, yes. CBD reduced alcohol intake with an SMD of -0.70, and CB-1 receptor inverse agonists produced a larger reduction, with an SMD of -1.21. These figures come from preclinical research rather than from [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) in people with alcohol use disorder. ### Did CB-1 agonists affect alcohol consumption in the review? Yes, in the opposite direction. In the preclinical meta-analyses, CB-1 agonists increased alcohol consumption, with an SMD of +0.66, while CB-1 receptor inverse agonists reduced intake, with an SMD of -1.21. These findings are preclinical. The human studies were too methodologically heterogeneous to combine in a meta-analysis, so there are no pooled human results to compare. ### Does a higher dose of CBD lead to a bigger reduction in drinking? Not in a simple way. The review’s dose-response analyses found non-linear effects for both CBD and CB-1 receptor inverse agonists, so a higher dose did not produce a proportionally larger drop in alcohol intake. These analyses come from preclinical research, since the human studies were too varied to pool, so they do not show how CBD dose affects drinking in people. ### What do human studies show about endocannabinoid treatments for alcohol use disorder? The human studies were too methodologically heterogeneous to combine in a meta-analysis, so the review could not produce pooled human results. This highlights that [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on endocannabinoid approaches to alcohol use disorder is still at an early stage, and the quantitative findings come from preclinical work. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41760917/”, “about”: “molecular psychiatry systematic review modulating endocannabinoid”, “isPartOf”: “Molecular psychiatry”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.](https://cedclinic.com/cbd-alcohol-use-disorder-treatment-research-systematic-review/) A comprehensive systematic review examining the therapeutic potential of targeting the endocannabinoid system in alcohol use disorder. [Read the full review](https://cedclinic.com/cbd-alcohol-use-disorder-treatment-research-systematic-review/) [Endocannabinoid System & Alcohol Use Disorder: Evidence from Preclinical & Human Studies](https://cedclinic.com/endocannabinoid-system-alcohol-use-disorder-evidence/) Detailed evidence synthesis from preclinical and human studies on the role of the endocannabinoid system in alcohol use disorder. [Explore the evidence](https://cedclinic.com/endocannabinoid-system-alcohol-use-disorder-evidence/) [Cannabis compounds reduce alcohol consumption in rats, study shows – leafie](https://cedclinic.com/cannabis-compounds-reduce-alcohol-consumption-in-rats-study-shows-leafie/) Study findings on how [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) impact alcohol consumption in animal models, highlighting potential therapeutic avenues. [Learn about the study](https://cedclinic.com/cannabis-compounds-reduce-alcohol-consumption-in-rats-study-shows-leafie/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).